Gallstones
Clinical Snapshot
Gallstones (cholelithiasis) are solid concretions that form within the gallbladder from precipitated components of bile. The large majority — roughly 80% — are cholesterol stones, forming when bile becomes supersaturated with cholesterol relative to the bile salts and phospholipids that normally keep it in solution, so that cholesterol crystals precipitate and aggregate.[1][2] The remainder are pigment stones: black pigment stones, composed of calcium bilirubinate from unconjugated bilirubin and classically associated with chronic hemolysis (e.g., sickle cell disease, hereditary spherocytosis) or cirrhosis; and brown pigment stones, associated with biliary infection or infestation.[1][2]
This chapter covers gallstones themselves — the majority that remain entirely silent, the biliary colic that develops when a stone transiently obstructs the cystic duct, and the medical (ursodiol-based) option for patients who are poor surgical candidates or decline surgery. It deliberately does not re-explain the acute emergency presentations that gallstones can progress to — acute cholecystitis, choledocholithiasis, ascending cholangitis, or gallstone pancreatitis — which this platform covers in its dedicated Cholecystitis chapter; this chapter cross-references that content rather than duplicating it.
Gallstone disease is common. The Canadian Association of General Surgeons cites an approximate 10% incidence in the general population, with prevalence highest (over 70%) in certain Indigenous populations — including the Pima and Chippewa of North America and the Mi'kmaq of Canada — and in South American Indigenous populations; intermediate (5-21.9%) in Caucasian, Asian, and African American populations; and lowest (under 5%) in Native African populations.[3] Canadian-specific data from the Canadian Liver Foundation puts prevalence at up to 20% in Canadian women and 10% in Canadian men by age 60, with 70-80% of the Canadian First Nations population affected.[2] The great majority of people with gallstones — roughly 80% — never develop symptoms at all; these are called silent gallstones and generally do not require treatment (see Choose Initial Treatment).[2][1]
Recognize the Condition
Asymptomatic (silent) gallstones
Most gallstones are discovered incidentally during imaging performed for an unrelated reason and never cause symptoms.[2][1] Progression to symptoms is genuinely uncommon: the Canadian Association of General Surgeons estimates that approximately 1-3% of individuals with asymptomatic or mildly symptomatic cholelithiasis develop significant symptoms annually,[3] closely matching a prospective American cohort in which only 1-2% per year developed biliary symptoms or a complication.[1] Longer-term data are reassuring in the same direction: in one 24-year follow-up of patients with incidentally discovered gallstones, only 28% still had demonstrable stones and only 6% had ever required a cholecystectomy.[1] This natural history is the basis for the observation-only approach to silent gallstones described in Choose Initial Treatment.
Biliary colic
Biliary colic is the characteristic symptomatic presentation of uncomplicated gallstone disease. It results from a stone (or thick sludge) transiently impacting the cystic duct: intraluminal pressure within the gallbladder rises, the organ distends, its wall stretches, and pain results; pain subsides once the transient obstruction relieves itself, typically as the stone falls back from the duct.[3] Pain is typically located in the right upper quadrant or epigastrium, often radiates to the back or right scapula, is frequently post-prandial, and is commonly triggered by a fatty meal; nausea and vomiting are common accompaniments.[3][1] The pain follows a genuine "colic" pattern — an acute rise in severity, a plateau of persistent pain, then gradual resolution — typically lasting from about 30 minutes to several hours, with most series describing resolution within about 4-6 hours.[3][1] Persistence of symptoms beyond about 6 hours is the single most useful clinical clue that the picture has evolved into acute cholecystitis rather than remaining simple biliary colic — see Red Flags/Refer, and this platform's dedicated Cholecystitis chapter for the full management of that presentation.[1]
Intractable biliary colic
A distinct pattern deserves its own recognition: some patients have the clinical picture of biliary colic, but symptoms recur with every meal or every attempt at oral intake, rather than resolving and staying resolved between episodes. This usually reflects a stone impacted at the gallbladder neck rather than one that transiently obstructs and releases, and these patients cannot reliably tolerate a sustainable diet — they need admission and cholecystectomy on an expedited basis, not another outpatient trial of analgesia and dietary advice.[3]
Distinguishing biliary colic from evolving cholecystitis
Between episodes of biliary colic, the physical examination is usually unremarkable and the patient is afebrile with a soft, non-tender abdomen. A tender, palpable gallbladder, a positive Murphy's sign, fever, or leukocytosis all point toward acute cholecystitis rather than simple biliary colic and should prompt management via this platform's Cholecystitis chapter rather than continued conservative management of "just gallstones."[3]
Risk Factors
Non-modifiable and modifiable risk factors combine to determine both the likelihood of forming gallstones and, to some extent, the stone type.
Risk factors by category
Non-modifiable
Age, female sex, ethnicity (see Clinical Snapshot for population-specific prevalence), family history, cirrhosis, Crohn's disease, and surgically altered anatomy — specifically terminal ileum resection, which impairs bile salt reabsorption and leads to cholesterol supersaturation of bile.[3]
Modifiable
Obesity (a body mass index over 35 kg/m² carries an odds ratio of 4.57 for gallstone disease),[1] rapid weight loss — including after bariatric surgery, where roughly 22% of patients develop gallstones[1] — type 2 diabetes (relative risk 1.65) and non-alcoholic fatty liver disease (odds ratio 1.55),[1] diet, and biliary stasis from pregnancy, total parenteral nutrition, or spinal cord injury.[3]
Medications — a genuinely pharmacist-relevant contributor
Several medication classes promote gallstone or biliary-sludge formation, and recognizing this in a patient with new gallstones or biliary-type symptoms is a real, actionable pharmacist contribution.
- Ceftriaxone forms an insoluble calcium-ceftriaxone precipitate in bile, producing biliary sludge or frank "pseudolithiasis" in a substantial proportion of treated patients (reported in 3-46% of courses, with higher rates in children, and with higher doses and longer courses) — this is usually reversible within 1-2 weeks of stopping the drug, and should be distinguished from a true, pre-existing gallstone rather than assumed to represent new chronic gallstone disease.[4]
- Octreotide reduces gallbladder motility and cholecystokinin release with ongoing use, and is associated with new gallstone formation in roughly half of patients after a year of therapy.[5]
- Fibrates — most clearly documented for clofibrate (an older agent no longer marketed), through inhibition of the ACAT enzyme system that renders bile more lithogenic — are a recognized, if less prominent, contributor with the fibrates still in use (gemfibrozil, fenofibrate); this does not argue against appropriate lipid-lowering therapy, but is worth considering in a patient on a fibrate who develops new gallstones or biliary colic.[5]
- Estrogen-containing therapy (hormone therapy, combined oral contraceptives) increases cholesterol secretion into bile and carries a real but modest risk (number needed to harm of 322).[1]
- Newer incretin-based diabetes therapies — DPP-4 inhibitors (odds ratio 1.22) and GLP-1 receptor agonists (relative risk 1.27) — carry a modest independent gallstone risk, compounded when they drive rapid weight loss; risk rises with more than 26 weeks of use.[1]
Pigment stones specifically
Chronic hemolysis (sickle cell disease, hereditary spherocytosis, and other hemolytic disorders) and cirrhosis are the classic drivers of black pigment stones, while biliary infection or infestation is associated with brown pigment stones.[1][2]
The "F" mnemonics
The classic bedside teaching mnemonic for gallstone risk is the "4 F's" — Female, Forty (increasing age), Fertile (multiparity/pregnancy), and Fat (obesity) — though gallstones occur across every age, sex, and body habitus. The Canadian Association of General Surgeons teaches an extended "6 F's" version that adds Fair (higher prevalence in Caucasian populations) and Family history.[3]
Red Flags & Refer
Any of the following means the presentation has moved beyond simple gallstones/biliary colic and needs management via this platform's Cholecystitis chapter (or, for pancreatitis, urgent medical assessment) rather than continued conservative gallstone management:
- Pain persisting beyond about 6 hours, rather than the self-limited several-hour course typical of biliary colic — this is the single most useful clue that the picture has evolved into acute cholecystitis.[3][1]
- Fever, a positive Murphy's sign, or leukocytosis — none of which accompany simple biliary colic.[3]
- Jaundice, hyperbilirubinemia, or elevated ALP/GGT — suggests choledocholithiasis (found in 10-20% of patients with symptomatic gallstones[1]) or, with fever and pain together (Charcot's triad), ascending cholangitis; a dilated common bile duct or a visible bile-duct stone on ultrasound should prompt MRCP or ERCP per the Cholecystitis chapter's pathway rather than reassurance.[3][1]
- Epigastric pain radiating to the back with elevated amylase or lipase — suggests gallstone pancreatitis, a distinct and potentially severe complication requiring urgent assessment, not managed in this chapter.[1]
- Intractable biliary colic — pain recurring with every meal or attempt at oral intake — signals a stone impacted at the gallbladder neck and the need for admission and expedited (not elective) cholecystectomy, not another outpatient analgesia trial.[3]
- Pregnancy with suspected gallstone-related pain beyond straightforward, brief biliary colic — gallbladder disease is the second most common cause of the acute abdomen in pregnancy and needs prompt assessment; see Special Populations.[3]
The pharmacist's role in any of these situations is prompt escalation — to the prescriber, to urgent/emergency care, or, for pancreatitis specifically, to emergency assessment — not attempting to manage them as ordinary biliary colic.
Assessment & Diagnosis
History
Characterize the pain: location (right upper quadrant or epigastric), radiation (back, right scapula), timing relative to meals (classically post-prandial, often triggered by fatty food), duration, and whether it fully resolves between episodes or recurs with every meal (see Recognize the Condition). Ask specifically about fever, jaundice, pale stools, and dark urine, which point toward a complication rather than simple gallstones, and review the medication list for a gallstone-promoting agent (see Risk Factors).
Physical examination
Examination between episodes of biliary colic is usually unremarkable — a soft, non-tender abdomen with no fever. A positive Murphy's sign, a tender or palpable gallbladder, or signs of jaundice point away from simple gallstones toward acute cholecystitis or a biliary-obstruction complication (see Red Flags/Refer).[3]
Laboratory testing
Basic labs are reasonable for any patient presenting with biliary-type pain: a complete blood count (looking for leukocytosis), an electrolyte/renal panel, and liver enzymes and function tests (AST, ALT, ALP, GGT, bilirubin, INR).[3] In simple biliary colic these are typically normal; an abnormal white cell count, transaminases, or bilirubin should prompt evaluation for cholecystitis or a bile-duct complication rather than being attributed to simple gallstones.[3]
Imaging
Right-upper-quadrant ultrasound is first-line: it is fast, inexpensive, avoids radiation, and readily identifies gallstones as a mobile, echogenic focus with posterior acoustic shadowing, with a reported sensitivity of 90-95%.[3] If choledocholithiasis is suspected (jaundice, dilated bile ducts, or a visible stone on ultrasound), MRCP (sensitivity 84%, specificity 92%) or endoscopic ultrasound (sensitivity 94%, specificity 89%, but invasive with a 4-10% complication rate) can further characterize the common bile duct — see the Cholecystitis chapter for the full biliary-obstruction pathway.[1]
Differential diagnosis
Peptic ulcer disease and gastroesophageal reflux, functional dyspepsia, acute cholecystitis, choledocholithiasis and ascending cholangitis, gallstone pancreatitis, and — particularly for atypical or diaphragmatic-radiating presentations — a cardiac or right-lower-lobe pulmonary cause should all be considered; see this platform's Undifferentiated Chest Pain chapter where the presentation genuinely overlaps.
Treatment Targets
- Confirm the diagnosis and exclude a complication (cholecystitis, choledocholithiasis, cholangitis, pancreatitis) before treating a presentation as simple gallstones or biliary colic.
- Relieve acute biliary colic pain effectively, using an NSAID-first approach rather than defaulting to opioids.
- Avoid treating asymptomatic (silent) gallstones found incidentally — observation is correct for the great majority.
- Offer definitive treatment — elective laparoscopic cholecystectomy — to appropriate surgical candidates with symptomatic gallstones, since recurrence without it is high.
- Reserve pharmacologic dissolution therapy (ursodiol) for carefully selected patients who are poor surgical candidates or decline surgery, with stone characteristics genuinely suited to it.
- Set realistic expectations for anyone starting ursodiol — this is a slow process measured in months, with a meaningful recurrence rate after stopping.
- Identify and address a modifiable medication-related contributor where one exists, in partnership with the prescriber.
- Recognize promptly when a presentation has moved beyond simple gallstones and escalate via the Cholecystitis chapter's pathway.
Choose Initial Treatment
Match management to how the gallstones are presenting
Asymptomatic, incidentally discovered gallstones observation — no treatment is needed for the great majority of patients.[2][1] Exceptions where prophylactic cholecystectomy is reasonably considered even without symptoms hemolytic anemia (sickle cell disease, hereditary spherocytosis), a planned solid-organ transplant, gallstones over 3 cm, and a porcelain (calcified) gallbladder.[1] Symptomatic biliary colic, suitable surgical candidate NSAID analgesia for the acute episode, with elective laparoscopic cholecystectomy as definitive treatment — this platform's Cholecystitis chapter covers the operative approach and perioperative details in full.[3] Symptomatic, poor surgical candidate or declines surgery oral ursodiol is a genuine option for carefully selected patients — see below.[2][1]
Why surgery is generally the answer for symptomatic gallstones
Once gallstones become symptomatic, they do not resolve on their own, and the risk of recurrent biliary colic — and of eventually progressing to a complication — is genuinely high without removing the gallbladder. Elective laparoscopic cholecystectomy is definitive treatment for the great majority of patients able to tolerate surgery, and is the pathway the Canadian Association of General Surgeons' own biliary-colic algorithm defaults to once an episode resolves.[3]
Acute pain management — NSAIDs first, not opioids
1st line an NSAID — the evidence here is genuinely strong, not simply a "safer alternative" framing: NSAIDs provide significantly greater relief of biliary pain than placebo (number needed to treat of 3) and than antispasmodics (number needed to treat of 3), with no difference in pain control compared with opioids.[1] A randomized trial of diclofenac given early in an attack of biliary colic also reduced progression to overt cholecystitis, reinforcing that NSAID analgesia here is not purely symptomatic.[6] Avoid defaulting to an opioid opioids carry more adverse effects than NSAIDs for equivalent pain relief in this setting; the older teaching that opioids should be specifically avoided in biliary pain because of sphincter of Oddi spasm is outdated and should not be the reason for withholding one when genuinely needed as an add-on for breakthrough pain.[1] See Pharmacologic Treatment Options and Drug Tables for specific agents and doses.
Ursodiol dissolution therapy — candidate selection, dosing, and genuinely important expectation-setting
Ursodiol (ursodeoxycholic acid) reduces hepatic cholesterol secretion into bile and decreases bile's cholesterol saturation, allowing small cholesterol gallstones to dissolve gradually over months.[2][1] Best candidates small, non-calcified, radiolucent ("floating," high-cholesterol-content) stones in a functioning gallbladder with a patent cystic duct, in a patient with mild symptoms who is a poor surgical candidate or who declines surgery — dissolution therapy is appropriate for only a minority of symptomatic patients overall.[1] Typical dosing is weight-based, around 8-10 mg/kg/day in 2-3 divided doses taken with food (per the product monograph); confirm the specific regimen against the current Drug Database entry.
Set expectations explicitly before starting therapy — this is one of the most important counselling points in this chapter. Ursodiol dissolution is slow: therapy is typically continued for at least 6-12 months, with reassessment by repeat ultrasound roughly every 6 months, and success rates vary widely by study and by stone characteristics — reported figures range from about 40-80% overall,[2] with more granular data showing roughly 47% dissolution at 6 months and 59% at 12 months, but complete dissolution in only about 28% at 24 months.[1] Recurrence after stopping is genuinely common — reported at about 50% by 5 years in one Canadian source[2] and about 49% at 11 years of follow-up in another series.[1] A patient who understands this timeline and recurrence risk up front is far better positioned than one who expects a quick fix.
Bariatric surgery / rapid intentional weight loss a separate, genuinely useful preventive indication: prophylactic ursodiol for roughly 6 months after bariatric surgery reduces new gallstone formation (number needed to treat of 5 to prevent any gallstone, 14 to prevent a symptomatic one, and 18 to prevent a cholecystectomy).[1] This is worth flagging proactively for any patient starting a bariatric or rapid-weight-loss program.
Non-Pharmacologic Treatment
- Elective laparoscopic cholecystectomy is definitive treatment for symptomatic gallstones in a suitable surgical candidate — see this platform's Cholecystitis chapter for the full operative approach, perioperative antibiotic stewardship, and postoperative care, which apply identically whether the indication was biliary colic or acute cholecystitis.
- Intractable biliary colic (recurring with every meal) needs admission and expedited cholecystectomy rather than elective scheduling, given the inability to tolerate oral intake.[3]
- A low-fat diet can reduce the frequency of biliary colic episodes while a patient awaits surgery or is managed medically, though it does not treat the underlying gallstones and is not a substitute for definitive treatment.
- Weight loss, where indicated, should be gradual rather than rapid — rapid or very-low-calorie weight loss is itself a recognized gallstone risk factor (see Risk Factors); supervise significant intentional weight loss medically.
- Extracorporeal shock-wave lithotripsy is a noninvasive option that has been used for symptomatic gallstones in patients avoiding surgery, but meaningful complication and recurrence rates have limited it to a niche, rarely used role today.[1]
Special Populations
Pregnancy
Gallbladder disease is the second most common cause of the acute abdomen in pregnancy after appendicitis.[3] Estimates of how often gallstones or biliary sludge develop during pregnancy vary by source — the Canadian Association of General Surgeons reports that 1-3% of pregnant women develop gallstones and about 30% develop sludge,[3] while an American series reports gallstones in up to 12% of pregnant women, with roughly 3% ultimately requiring an intrapartum cholecystectomy.[1] Avoid NSAIDs, particularly from around 20 weeks' gestation onward, given fetal renal and other risks — acetaminophen is the preferred analgesic for biliary colic pain in pregnancy, with an opioid reserved for pain not controlled by acetaminophen alone. Do not start ursodiol dissolution therapy for gallstones in pregnancy — the months-long treatment course is not compatible with a time-limited pregnancy, and definitive management, if needed, is surgical; see this platform's Cholecystitis chapter for the operative approach in pregnancy, and the Cholestasis of Pregnancy chapter for the distinct, unrelated use of ursodiol in that condition.
Breastfeeding
Ibuprofen and other short-acting NSAIDs, acetaminophen, and standard opioid analgesics are generally considered compatible with breastfeeding at standard doses; confirm specifics against each drug's own Drug Database entry. Data on ursodiol in breastfeeding are limited, but available information does not suggest a significant risk; given the elective, months-long nature of dissolution therapy, deferring it is usually reasonable if surgery is a genuine alternative.
Pediatrics
Gallstones are less common in children than in adults but are rising in parallel with pediatric obesity; hemolytic disease (sickle cell disease, hereditary spherocytosis) remains a disproportionate driver of pigment stones in this population.[1] Use weight-based NSAID/analgesic dosing per a pediatric dosing reference, and manage symptomatic disease with the same observation-versus-cholecystectomy framework used in adults.
Older adults
Gallstone prevalence rises with age, and older adults are more likely to present atypically or to already have a complication (cholecystitis, choledocholithiasis) by the time they are assessed — maintain a lower threshold for imaging and for considering a complication rather than assuming simple biliary colic.
Cirrhosis and hepatic impairment
Pigment gallstones are common in cirrhosis, and surgical risk is meaningfully elevated in this population — cholecystectomy decisions should involve a surgeon experienced with cirrhotic patients. Avoid or use cautiously NSAIDs in cirrhosis, given bleeding and renal risk; acetaminophen, used cautiously with a lower total daily dose, is generally the safer default analgesic. Note that mild transaminase or bilirubin elevation can reflect the underlying liver disease itself rather than a gallstone complication — interpret labs in that context.
Bariatric surgery / rapid intentional weight loss
This population deserves proactive counselling rather than reactive management: prophylactic ursodiol for roughly 6 months after bariatric surgery meaningfully reduces new gallstone formation, symptomatic gallstones, and eventual cholecystectomy (see Choose Initial Treatment for the specific numbers).[1]
Renal impairment
Avoid or use ketorolac and other NSAIDs cautiously in significant renal impairment; dose-adjust hydromorphone and other opioids as needed. Ursodiol is primarily hepatically handled and generally does not require specific renal dose adjustment, but confirm against the current product monograph.
Populations with a higher baseline prevalence
Certain Indigenous populations — including several Canadian First Nations communities — have a substantially higher prevalence of gallstone disease than the general population (see Clinical Snapshot and Risk Factors).[3][2] This is a genuine epidemiologic reality worth knowing, not a reason to alter the clinical approach to an individual patient — the same observation-versus-treatment framework applies regardless of ethnicity, and the higher population prevalence should not translate into either under- or over-investigating an individual patient's actual symptoms.
Monitoring & Follow-Up
- For a patient managed with observation alone (asymptomatic gallstones): no routine monitoring is needed beyond ensuring the patient knows the return precautions below — repeat imaging "just to check" is not indicated for stable, asymptomatic disease.
- For acute biliary colic managed as an outpatient with NSAID analgesia: confirm pain resolves within the expected several-hour window, and give explicit return precautions — pain lasting beyond about 6 hours, fever, jaundice, or inability to tolerate oral intake — rather than leaving follow-up entirely to the patient's discretion.[3][1]
- For a patient started on ursodiol: schedule a repeat ultrasound at around 6 months to assess dissolution progress, and again at 12 months if therapy continues; discontinue if there has been no meaningful reduction in stone size/number by 12 months, or sooner if symptoms progress or a complication develops (see Treatment Failure/Next Step).[2][1] Confirm the patient still understands the recurrence risk after any eventual stop.
- For a patient scheduled for elective cholecystectomy: counsel on what to expect afterward, since patients often ask a pharmacist rather than their surgeon about minor postoperative symptoms — postcholecystectomy diarrhea (reported in roughly 13% of patients, thought to reflect excess bile acid delivery to the colon, usually improving over time and responsive to cholestyramine if persistent) and a broader postcholecystectomy syndrome of ongoing GI symptoms (abdominal pain, bloating, dyspepsia) in roughly 5-10% of patients are common enough to mention proactively.[1] Full postoperative monitoring is covered in this platform's Cholecystitis chapter.
- For any patient on a gallstone-promoting medication (see Risk Factors) who develops new biliary-type symptoms: reassess the ongoing need for that medication with the prescriber rather than only treating the gallstone in isolation.
Common Errors to Avoid
- Treating asymptomatic (silent) gallstones found incidentally with cholecystectomy or ursodiol "just in case" — observation is correct for the great majority.
- Reaching for an opioid first-line for biliary colic pain, based on the outdated assumption that NSAIDs are inadequate or that opioids are somehow safer for biliary pain — the evidence shows NSAIDs are at least as effective with fewer adverse effects.
- Starting ursodiol without confirming the stone is genuinely suited to it (small, non-calcified, radiolucent, in a functioning gallbladder with a patent cystic duct) — most symptomatic patients are not good candidates.
- Starting ursodiol without explicitly counselling on the months-long timeline and the meaningful recurrence risk after stopping — a patient who expects a quick, permanent fix is being set up for disappointment and potentially for silently discontinuing an otherwise-appropriate therapy.
- Treating pain persisting beyond several hours, fever, or jaundice as "just a bad episode of biliary colic" rather than recognizing evolution to cholecystitis, cholangitis, or pancreatitis.
- Missing intractable biliary colic (recurring with every meal) as a distinct pattern needing admission and expedited surgery, rather than another round of outpatient analgesia.
- Missing a medication-induced contributor (ceftriaxone, octreotide, a fibrate, or a GLP-1 receptor agonist/DPP-4 inhibitor, especially alongside rapid weight loss) in a patient with new gallstones or biliary-type symptoms.
- Overlooking pigment-stone risk factors (hemolysis, cirrhosis) in a patient who does not fit the classic "4 F's" cholesterol-stone profile.
- Prescribing or continuing NSAIDs for biliary colic pain in a patient who is late in pregnancy, or in significant renal impairment or active GI bleeding risk, without considering acetaminophen or another alternative.
Clinical Decision Algorithm
Drug Tables
How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.
Analgesia for Acute Biliary Colic
NSAIDs relieve biliary pain at least as effectively as opioids, with fewer adverse effects — use as first-line therapy rather than defaulting to an opioid.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Ibuprofen | Adults: 400-600 mg PO every 6-8 hours PRN, maximum per label | GI upset/bleeding, renal impairment | Increased bleeding risk with anticoagulants; avoid with other NSAIDs | First-line oral option when oral therapy is feasible |
| Ketorolac tromethamine | Adults: 15-30 mg IV every 6 hours | GI bleeding, renal impairment, platelet inhibition | Increased bleeding risk with anticoagulants; avoid with other NSAIDs | Limit to 5 days total; avoid in significant renal impairment, active GI bleeding risk, or pregnancy |
| Diclofenac potassium | Adults: 50 mg PO 2-3 times daily PRN, per product monograph | GI upset/bleeding, renal impairment | Increased bleeding risk with anticoagulants; avoid with other NSAIDs | The specific NSAID studied for reducing progression of biliary colic to overt cholecystitis |
| Acetaminophen | Adults: 975-1000 mg PO/IV every 6 hours, maximum 4 g/day (lower in hepatic impairment) | Hepatotoxicity with overdose or significant hepatic impairment | None significant at standard doses | Reasonable when an NSAID is contraindicated, though it does not match NSAID efficacy for biliary pain |
Opioid Analgesia — Reserve for Breakthrough Pain
The older concern about opioid-induced sphincter of Oddi spasm is outdated and not a reason to withhold one when genuinely needed; reserve for pain not controlled by scheduled NSAID/acetaminophen, given more adverse effects than NSAIDs at equivalent efficacy.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Hydromorphone | Adults: 0.2-0.5 mg IV every 3-4 hours PRN | Respiratory depression, sedation, constipation, nausea | Additive CNS/respiratory depression with other sedatives | Preferred over morphine in significant renal impairment given more predictable metabolite handling |
| Morphine | Adults: 2-4 mg IV every 3-4 hours PRN | Respiratory depression, sedation, constipation, nausea | Additive CNS/respiratory depression with other sedatives | An acceptable alternative to hydromorphone for breakthrough pain |
Antiemetic
For nausea and vomiting accompanying acute biliary colic.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Ondansetron | Adults: 4 mg IV/PO, may repeat per the product monograph | Headache, QTc prolongation at higher/repeated doses | Additive QTc prolongation with other QTc-prolonging drugs | First-line for nausea and vomiting |
Oral Dissolution Therapy — Selected Non-Surgical Candidates
For symptomatic patients who are poor surgical candidates or decline surgery, with stone characteristics genuinely suited to dissolution (small, non-calcified, radiolucent, functioning gallbladder with a patent cystic duct). Also used as bariatric-surgery gallstone prophylaxis. Confirm candidacy and counsel explicitly on the slow timeline and meaningful recurrence risk before starting.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Ursodiol | Gallstone dissolution: Approximately 8-10 mg/kg/day in 2-3 divided doses with food, per the product monograph, continued 6-12+ months Bariatric-surgery prophylaxis: Per the product monograph, typically for about 6 months post-operatively | Generally well tolerated; diarrhea occasionally reported | None significant at standard doses | Success rates and duration vary by stone characteristics; reassess by ultrasound roughly every 6 months and discontinue if no meaningful response by 12 months |
Medications Associated with Gallstone or Biliary Sludge Formation — Review, Not Routine Discontinuation
Recognizing a medication-related contributor is a genuine pharmacist contribution; weigh against the drug's own benefit and involve the prescriber rather than stopping unilaterally.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Ceftriaxone | Typical use: Broad-spectrum antibiotic therapy | Biliary sludge/pseudolithiasis in a substantial proportion of treated patients (reported 3-46%), from a calcium-ceftriaxone precipitate; usually reversible within 1-2 weeks of stopping | n/a for this indication | Higher risk with higher doses, longer courses, and in children; confirm a new finding is drug-related pseudolithiasis rather than a true chronic gallstone before treating it as one |
| Octreotide | Typical use: Long-term somatostatin analogue therapy | New gallstone formation in roughly half of patients after 1 year of therapy, via reduced gallbladder motility and cholecystokinin release | n/a for this indication | Risk rises with treatment duration; periodic gallbladder ultrasound is reasonable during long-term therapy, though routine prophylactic cholecystectomy is not |
| Gemfibrozil | Typical use: Lipid-lowering therapy | May modestly increase bile cholesterol saturation/lithogenicity | n/a for this indication | The mechanism is most clearly established for clofibrate, an older agent no longer marketed; not a reason for routine avoidance, but worth considering in a patient who develops gallstones while on fibrate therapy |
| Fenofibrate | Typical use: Lipid-lowering therapy | May modestly increase bile cholesterol saturation/lithogenicity | n/a for this indication | As for gemfibrozil — weigh against the drug's lipid-lowering benefit rather than avoiding routinely |
References
- Gallstone Disease: Common Questions and Answers — American Family Physician (Patel H, Jepsen J). Am Fam Physician 2024;109(6):518-524
- Gallstones — Canadian Liver Foundation (Sloan P). Canadian Liver Foundation patient information sheet, current for March 2012
- Biliary Colic & Cholecystitis — Dynamic Practice Guidelines for Emergency General Surgery, Committee on Acute Care Surgery, Canadian Association of General Surgeons (Aubin JM, Ball CG). CAGS Dynamic Practice Guidelines for Emergency General Surgery, Chapter 8, 2018
- Ceftriaxone — LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox [Internet], updated 2021 Dec 20
- Drug-Induced Gallbladder Disease — Drug Safety (Michielsen PP, Fierens H, Van Maercke YM). Drug Saf 1992;7(1):32-45
- Treatment of biliary colic with diclofenac: a randomized, double-blind, placebo-controlled study — Gastroenterology (Akriviadis EA, Hatzigavriel M, Kapnias D, Kirimlidis J, Markantas A, Garyfallos A). Gastroenterology 1997;113(1):225-231
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.